AFP and neoplasm: Kudo et al. proposed that the criteria for discontinuing the drug (drug-off criteria) should be: (1) mRECIST CR achieved by TACE or RFA; (2) Sustained normalization of all three tumor markers (AFP, DCP, AFP-L3) for 12–24 weeks or longer; (3) Contrast-enhanced echocardiography showing the loss of intra-tumoral blood flow [7].